Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

Clinical trial NCT07224100 · RECRUITING

Trial details

NCT number: NCT07224100
Sponsor: University of Washington
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1 Lymphoblastic Lymphoma

Start date: 2026-03-30
Primary completion: 2028-07-31
Enrollment: 33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.